News

EFMC Award 2027 - Call for Nominations

The EFMC-WuXi AppTec Award for Excellence in Chemical Biology recognises outstanding research in chemical biology, as defined by EFMC in "The Chemical Biology-Medicinal Chemistry Continuum: EFMC’s Vision", ChemBioChem 2021, 22, 2823–2825.

Presented biennially, the Award consists of a diploma, 7.500€, and an invitation to deliver a lecture at EuroChemBio 2027, which will take place in Milan, Italy, from October 5 to 8, 2027.

The Award has been established with the support of WuXi AppTec.

Candidates should have a track record of significant research achievements in chemical biology during the past 10 years, demonstrating the originality and impact of their contributions.

The Award is open to scientists who will not be older than 50 years* on January 1st, 2027 and whose achievements have not previously been recognised by another EFMC award.

*In line with EFMC’s core values of equal opportunities and inclusiveness, maternity leave and career breaks taken for health or personal reasons will be considered during the final selection process.

Nomination packages should include:

  • a one-page letter proposing the candidate;
  • a brief biographical sketch, including a list of selected publications;
  • two one-page letters of support.

Self-nominations are also accepted.

Nomination deadline: January 31, 2027

The awardee will be announced around March 2027.

EFMC Prizes 2027 - Call for Nominations

To acknowledge and recognise outstanding researchers (≤ 12 years after PhD) working in European industry and academia, the EFMC established the "EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Industry" and the "EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Academia".

These two prizes are given annually and consist of a diploma, 2.500€ and an invitation to give an oral communication at the EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC Synthetic and Medicinal Chemistry 2027), scheduled to be held in Edinburgh, Scotland from August 30 to September 2, 2027. Two additional nominees will also be identified and acknowledged as most meritorious runners-up.

Deadline for nominations is January 31, 2027.

EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Industry

Nominations should be written by the candidate’s supervisor and consist of:

  • a one-page nomination letter from the supervisor;
  • a brief CV of the candidate;
  • an abstract of the proposed oral presentation.

EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Academia

Applications should consist of:

  • a one-page letter from the candidate, including a brief rationale for their application;
  • a one-page list of the candidate’s five most important publications;
  • a brief CV of the candidate;
  • an abstract of the proposed oral presentation.

EFMC Awards 2026 - Laureates announced

The EFMC is excited to announce the names of the 2026 Award winners. We are proud that, this year again, the awardees could be chosen from a large selection of outstanding medicinal chemists and chemical biologists.

Prof. Stefan Laufer (University of Tübingen, Germany)

For his exceptional, impressive and long-standing contributions to medicinal chemistry and drug discovery. Throughout his career, Professor Laufer has combined scientific excellence, innovation, and leadership to advance the development of novel therapeutic approaches, particularly in the field of kinase inhibitors and inflammation research. Beyond his highly influential scientific achievements, he has played a pivotal role in shaping and strengthening the medicinal chemistry community across Europe. Through his mentorship, collaborations, and commitment to scientific exchange, he has inspired generations of scientists and helped elevate the impact and visibility of our field worldwide.

Prof. Christian Hackenberger (Leibniz-Institute for Molecular Pharmacology, Germany)

For his truly outstanding contributions at the interface of chemistry and biology, particularly through his pioneering work in bioconjugation. Prof. Hackenberger as developed innovative methodologies, such as P5-labeling, that have profoundly advanced the field and have been widely translated in the design of antibody-drug conjugates and in strategies to improve the cellular permeability of biopharmaceuticals. His work, combining deep scientific creativity with a strong translational vision, transformed elegant chemical concepts into approaches with real therapeutic potential, and is widely regarded as a major driver shaping the next generation of therapeutic innovation.

Prof. Timothy Noël (University of Amsterdam, The Netherlands) 
 
For his outstanding contributions to the development of transformative technologies in modern drug discovery. Through pioneering work combining flow chemistry, photochemistry, electrochemistry, and automation, Professor Noël has opened entirely new possibilities for accessing chemical space in a safer, faster, and more sustainable manner. What makes his achievements particularly remarkable is the way he bridges cutting-edge innovation with practical industrial application, enabling technologies that are now widely embraced across academia and pharma. His vision, creativity, and translational impact have made him one of the leading scientific innovators shaping the future of medicinal chemistry and chemical synthesis.
 
All 3 awards consist of a diploma, 7.500€ and an invitation to give a headline presentation at the EFMC International Symposium on Medicinal Chemistry (EFMC Medicinal Chemistry).

The 2026 Awards will be presented at the EFMC International Symposium on Medicinal Chemistry (EFMC Medicinal Chemistry 2026), scheduled to take place in Basel, Switzerland on September 6-10, 2026.

Awardees of the 2026 Klaus Grohe Prize

The 2026 Klaus Grohe Prize will be awarded to Professor Dr Edward Tate, Imperial College London, United Kingdom, and Professor Dr Nicolas Winssinger, University of Geneva, Switzerland.

For the first time, two awardee will share the award, and for the first time, it will be endowed with €75,000 – making the Klaus Grohe Prize one of the most prestigious prizes for medicinal chemistry in Europe.

It is awarded by the Klaus Grohe Foundation, which is affiliated with the German Chemical Society (GDCh). The award ceremony will take place on September 6, 2026, during the EFMC Medicinal Chemistry 2026 Conference in Basel, Switzerland.

At the same event, on September 9, 2026, the 2026 Klaus Grohe Young Scientist Award will be presented to Dr Sebastian Pomplun, Leiden University, Netherlands.

EFMC Statement on EU Proposal to Ban PFAS

The EU, through the European Chemicals Agency (ECHA), has launched a proposal that aims to extensively restrict the manufacture, supply, and use of all per- and polyfluoroalkyl substances. PFAS include a vast range of fluoroalkyl materials, ranging from simple fluorinated reagents and starting materials used in drug discovery and development (including the synthesis of active pharmaceutical ingredients), to thermoplastic polymers found in laboratory commodities such as stirring bars or O-rings. Several PFAS are environmental pollutants and some of them have detrimental effects on human health. Their extensive use throughout the society, combined with the low reactivity displayed by many fluoroalkyl chemicals, magnifies the potential for accumulation in the environment and contamination of food and water supplies.

However, the entire ban of these materials can lead to major disruptions in all research, development, and innovation activities related to medicinal chemistry and chemical biology. Ultimately, it can have long-term implications on the innovation potential of EU research.

Importantly, there are currently a significant number of compounds in clinical use or in Phase III of clinical trials (the last stage before approval and marketing) containing fluorinated groups such as CF3 and CF2, or combination of both, in their structure. These are life-saving compounds, and thus a transition period should be considered to enable a detailed analysis of the socio-economic impacts of a ban in the short-term and to find efficient, safe and economically viable alternatives.

Course Material on Best Practices in Medicinal Chemistry

Wondering how researchers work in other companies or in academia? Are there important trends or new technologies that you may have missed? Looking for general guidelines or tips and tricks on important topics in drug discovery?

EFMC is tackling this challenge with a team of experienced practitioners from industry and academia, and is sharing training and course materials in several formats: freely accessible webinars on the EFMC youtube channel, educational slide decks and case studies.

These are freely accessible for personal use or for use in further training or teaching material, so have a look and spread the news! 

  • Validating Chemical Probes

What are chemical probes and why are they important? Chemical probes are designed to selectively address a biological question; this is distinctly different from a drug, which is designed to produce a clinical outcome! Simple guidelines can be used to generate high-quality chemical probes and obtain reliable data to further our understanding of human biology and disease.

Link to the material.

  • Phenotypic Drug Discovery (PDD)

Recent years have seen a renaissance of Phenotypic drug discovery (PPD) with novel screening technologies and a track record that is thought to match or surpass that of target-centric approaches. We present a view on best practices to consider when running phenotypic drug discovery campaigns to increase the chance of success of these black box approachs.

Link to the material.

  • Hit Generation

Hit Generation is a crucial step of all drug discovery campaigns that will determine the speed and chance of success of identifying drug candidates.

We cover the essential approaches for hit generation and the opportunities and challenges they come with. We then provide guidance on how to validate hits to ensure medicinal chemistry is only performed on compounds and scaffolds that engage the target of interest and have the desired mode of action. Finally, we discuss the design of integrated hit generation strategies that combine several approaches to maximize the chance of identifying high quality starting points.

Link to the material.

EFMC Statement on the Invasion of Ukraine

As we reached the tragic first anniversary of Russia's invasion of Ukraine, EFMC renews its strong condemnation of the actions taken by the Russian government and expresses its support to the scientific community and to the Ukrainian people.

Being an independent learned society supporting all members of the medicinal chemistry and chemical biology community, EFMC however believes that scientific researchers in Russia should not be outcasted because of the actions of their government. True to our principles, we aim towards promoting cooperation and encouraging exchanges between scientific researchers in Europe and around the World.

Chemistry Europe Signs Collaboration Agreement with EFMC

Chemistry Europe journals ChemMedChem and ChemBioChem to become official journals of European Federation for Medicinal Chemistry and Chemical Biology (EFMC)

Weinheim, Germany; Bern, Switzerland; April 5, 2022 — Chemistry Europe, an association of 16 chemical societies from 15 European countries publishing a family of high-quality scholarly chemistry journals, today announced that it has entered into a multi-year collaboration with the European Federation for Medicinal Chemistry and Chemical Biology (EFMC), an independent association representing 29 scientific organizations from 25 European countries to advance the science of medicinal chemistry and chemical biology. Under the terms of the agreement, the Chemistry Europe journals ChemMedChem and ChemBioChem will become official journals of EFMC.

The collaboration agreement aims to increase the visibility of ChemMedChem and ChemBioChem, bring valuable additional benefits to readers, authors, and early-career researchers, and thus strengthen the science of medicinal chemistry and chemical biology. ChemMedChem and ChemBioChem will become official journals of EFMC but continue to be owned by Chemistry Europe. The journals will display the label "official journal of EFMC" on their covers.

“We are looking forward to starting our collaboration with the EFMC. Our partnership is not only expected to increase the visibility of our journals ChemMedChem and ChemBioChem, but more importantly to strengthen the impact of the research of the European scientific community of medicinal chemistry and chemical biology on the wider global scenario. A number of exciting editorial projects will be developed within this agreement, also highlighting the contribution of young researchers.” says Professor Gianluca Farinola, Chemistry Europe Council Member in charge of ChemMedChem and Vice President of Società Chimica Italiana.

“We are very happy for this new step in the collaboration with Chemistry Europe, which allows for a broader dissemination and visibility of the excellent research carried out by the medicinal chemistry and chemical biology communities across Europe”, says Professor Rui Moreira, President of the EFMC.

Chemistry Europe publishes 19 high-quality scientific chemistry journals covering a very wide range of disciplines and supports scientists at every stage of their careers. EFMC promotes and strengthens the science of medicinal chemistry and chemical biology by organizing symposia and short courses, sponsoring meetings and schools, publishing on relevant topics, and presenting awards and prizes. The collaboration underscores the commitment of Chemistry Europe and EFMC to strengthen the scientific excellence of chemistry researchers from around the world.

Link https://www.chemistryviews.org/details/advertorial/11346095/Chemistry_Europe_Signs_Collaboration_Agreement_with_EFMC.html

Media Contact:
Dr. Vera Koester
Editor in Chief ChemistryViews (The Magazine of Chemistry Europe)
vkoester@wiley-vch.de
++49(0)172 3999 826

Mr Brieuc Matagne
EFMC Administrative Secretariat
administration@efmc.info

About Chemistry Europe

Founded in 1995, Chemistry Europe is an association of 16 chemical societies from 15 European countries, representing over 75,000 chemists. It publishes a family of high-quality scholarly chemistry journals, covering a very broad range of disciplines. Wiley-VCH is their publisher.

The mission of Chemistry Europe is to evaluate, publish, disseminate, and amplify the scientific excellence of chemistry researchers from around the globe in high-quality publications. It supports its members at every stage of their careers as they strive to solve the challenges that impact humankind. In all its work, Chemistry Europe values integrity, openness, diversity, cooperation, and freedom of thought. https://chemistry-europe.onlinelibrary.wiley.com/

About European Federation for Medicinal Chemistry and Chemical Biology (EFMC)

The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) is an independent association founded in December 1969 that represents 29 scientific organizations from 25 European countries. Its objective is to advance the science of medicinal chemistry & chemical biology by promoting cooperation and encouraging strong links between the national adhering organizations in order to deepen contacts and exchanges between medicinal chemists & chemical biologists in Europe and around the World. EFMC fulfills this objective by organizing symposia and short courses, by sponsoring meetings and medicinal chemistry schools, by publishing on relevant topics and by conferring awards and prizes. https://www.efmc.info/

About Wiley-VCH

Originally founded in 1921 as Verlag Chemie, Wiley-VCH plays an important role in providing scientists, engineers, and economists with high-quality information. Its integration within the global John Wiley & Sons Group since 1996 allows the company to distribute its program in every country on this planet. Our strength is based on our joint endeavors and success with people all over the world. From the very beginning, the publishing program covers most areas of the natural sciences, such as chemistry, physics, life sciences, medicine, engineering, and now also economics. While such information has traditionally been published in the form of journals, databases, reference works and books, online and offline services are now becoming increasingly important, alongside inter- and transdisciplinary portals. The company's staff in Weinheim, Berlin, and Zurich represent the foundation of all our services with their professional expertise and experience. https://www.wiley-vch.de/en/

EFMC supports the "Stick to Science" Initiative

EFMC is proud to support the ‘Stick to Science’ campaign, launched on 8 February, urging EU leaders, as well as the UK and Swiss governments, to place science collaboration before politics, and to quickly reach the UK’s and Switzerland’s association to Horizon Europe. Since the launch, the campaign has reached close to 4 million people on Twitter, and gathered a total of over 3400 signatures.

If you haven’t signed up to the initiative yet, please do so! These signatures are important in ensuring that we get the attention of European leaders and secure association to Horizon Europe. The initiative is open for all to sign, both as an individual or as an organisation on the dedicated website.

The site also includes a range of resources for supporters, including suggested social media posts, banners and email signature templates.

A Job/PhD or Post-Doc position to offer in medicinal chemistry or chemical biology? Use the EFMC Job Portal

The posting of Job/PhD & Post-Doc offers is free and is available for any Med Chem related jobs, in industry as well as academic positions.

Job posting is now made even simplier, you only have to provide the URL of the job application. 

Once reviewed, the position will be available on the EFMC website and in the monthly newsletter "MedChemWatch".